Danaher Corporation
NYSE•DHR
CEO: Mr. Steven M. Rales
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1978-12-29
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
Contact Information
2200 Pennsylvania Avenue, North West, Suite 800 West, Washington, DC, 20037-1701, United States
202-828-0850
Market Cap
$131.71B
P/E (TTM)
36.5
30.8
Dividend Yield
0.7%
52W High
$242.80
52W Low
$171.00
52W Range
Rank31Top 21.6%
5.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$6.84B+4.59%
4-Quarter Trend
EPS
$1.69+12.67%
4-Quarter Trend
FCF
$1.75B+16.17%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Total Sales Increased 3.0% Total sales reached $24.57B USD, marking 3.0% growth; core sales increased 2.0% driven by Biotechnology segment strength.
Biotechnology Segment Profit Growth Biotechnology operating profit grew to $1.86B USD, reflecting 6.5% core sales growth led by increased consumables demand.
Cash Position Strengthened Cash and equivalents totaled $4.62B USD by year-end 2025, significantly increasing from $2.08B USD reported previously.
Goodwill Increased to $43.15B Goodwill balance grew to $43.15B USD, reflecting acquisition activity; total assets reached $83.46B USD.
Risk Factors
Operating Margin Compression Noted Operating profit margin fell 130 basis points to 19.1% due to 2025 impairment charges and currency impacts.
Life Sciences Core Sales Decline Life Sciences core sales declined 1.5% due to lower funding for emerging biotech customers and academic markets.
Increased Outstanding Debt Total outstanding debt increased to $18.42B USD, potentially limiting operations and future cash flow flexibility.
Healthcare Regulation Exposure Extensive government regulation in healthcare, data privacy, and trade compliance presents ongoing legal and financial risks.
Outlook
Masimo Acquisition Pending Definitive agreement signed to acquire Masimo Corporation for $9.9B cash, expected to integrate into Diagnostics segment.
Diagnostics Growth Expected Diagnostics segment anticipates higher sales growth in 2026, moving past peak headwinds caused by recent healthcare policy changes in China.
Focus on Portfolio Enhancement Strategy centers on strengthening DBS application, enhancing portfolio via strategic capital allocation, and retaining exceptional talent globally.
Commercial Paper Refinancing Plan Plans to refinance maturing commercial paper using available cash, Credit Facility capacity, or accessing capital markets when favorable.
Peer Comparison
Revenue (TTM)
$397.96B
$62.58B
$52.71B
Gross Margin (Latest Quarter)
86.8%
81.9%
74.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| AMGN | $198.26B | 25.7 | 96.7% | 60.3% |
| GILD | $180.27B | 21.2 | 41.0% | 41.7% |
| TMO | $176.79B | 26.6 | 13.1% | 37.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
6.0%
Steady Growth
4Q Net Income CAGR
7.9%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Apr 20, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data